Valuation: Harbin Gloria Pharmaceuticals Co., Ltd

Market Cap 657.81Cr 99Cr 89Cr 82Cr 74Cr 138.48Cr 9.4TCr 140.15Cr 978.52Cr 389.75Cr 4.92TCr 370.25Cr 362.43Cr 16TCr P/E 2024
24.2x
P/E 2025 18.2x
Enterprise Value 574.01Cr 86Cr 77Cr 71Cr 65Cr 120.84Cr 8.2TCr 122.3Cr 853.86Cr 340.1Cr 4.29TCr 323.08Cr 316.26Cr 14TCr EV / Sales 2024
2.12x
EV / Sales 2025 2.82x
Free-Float
90.2%
Yield 2024 *
-
Yield 2025 -
27/08 HARBIN GLORIA PHARMACEUTICALS Co., LTD Reports Earnings Results for the Half Year Ended June 30, 2026 CI
27/04 HARBIN GLORIA PHARMACEUTICALS Co., LTD Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
14/04 HARBIN GLORIA PHARMACEUTICALS Co., LTD Reports Earnings Results for the Full Year Ended December 31, 2025 CI
16/01 Harbin Gloria Pharmaceuticals Co., Ltd Approves Election of Xu Yuhong as Independent Director, Effective 14 January 2026 CI
28/25/28 HARBIN GLORIA PHARMACEUTICALS Co., LTD Reports Earnings Results for the Nine Months Ended September 30, 2025 CI
26/25/26 HARBIN GLORIA PHARMACEUTICALS Co., LTD Reports Earnings Results for the Half Year Ended June 30, 2025 CI
04/25/04 Harbin Gloria Pharmaceuticals Gets Right to Market Eisai's Mecobalamin Injection MT
27/25/27 Harbin Gloria Pharmaceuticals Signs Co-Promotion Deal for Lipid Drug MT
25/25/25 HARBIN GLORIA PHARMACEUTICALS Co., LTD Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
18/25/18 HARBIN GLORIA PHARMACEUTICALS Co., LTD Elects Liu Yueyin as A Non-Independent Director CI
14/25/14 Tranche Update on HARBIN GLORIA PHARMACEUTICALS Co., LTD's Equity Buyback Plan announced on October 22, 2024. CI
13/25/13 HARBIN GLORIA PHARMACEUTICALS Co., LTD's Equity Buyback announced on October 22, 2024, has closed with 32,307,224 shares, representing 1.42% for CNY 79.99 million. CI
10/25/10 Tranche Update on HARBIN GLORIA PHARMACEUTICALS Co., LTD's Equity Buyback Plan announced on October 22, 2024. CI
1 day+1.37%
1 week-8.95%
Current month-19.18%
1 month-14.49%
3 months+2.43%
6 months-18.28%
Current year-3.91%
1 week 2.87
Extreme 2.87
3.09
1 month 2.87
Extreme 2.87
3.78
Current year 2.37
Extreme 2.37
5.1
1 year 2.37
Extreme 2.37
5.1
3 years 1.66
Extreme 1.66
5.1
5 years 1.66
Extreme 1.66
5.1
10 years 1.66
Extreme 1.66
9.8
Manager TitleAgeSince
Chief Executive Officer 53 26/12/2022
Corporate Officer/Principal 42 18/04/2018
Corporate Officer/Principal 40 23/05/2019
Director TitleAgeSince
Director/Board Member 40 14/03/2025
Director/Board Member 53 11/11/2022
Director/Board Member 42 11/11/2022
Date Insider Type Main position Quantity % Market Cap. Importance
02/07/25 Sell 5,87,500 0.0283%
02/07/25 Sell

Director

2,59,600 0.0125%
02/07/25 Sell 5,87,500 0.0283%
Change 5-day change 1-year change 3-year change Capi.($)
+1.37%-8.95%-7.81%+21.40% 97Cr
+0.50%+1.38%+57.09%+129.96% 1,14300Cr
+0.86%+5.14%+45.00%+86.15% 65TCr
-0.14%+0.42%+25.69%+105.85% 51TCr
-0.05%+1.73%+52.74%+67.74% 38TCr
-0.63%-5.97%+61.93%+37.06% 35TCr
+0.34%+1.84%+30.70%+54.27% 29TCr
-0.45%+1.19%+2.89%+26.08% 26TCr
+0.87%+3.08%+54.69%+72.74% 24TCr
+0.08%+3.67%+35.05%+107.78% 20TCr
Average +0.28%+0.46%+35.80%+70.90% 40.29TCr
Weighted average by Cap. +0.25%+0.71%+44.49%+89.00%

Financials

2024 2025
Net sales 244.07Cr 37Cr 33Cr 30Cr 28Cr 51Cr 3.49TCr 52Cr 363.07Cr 144.61Cr 1.82TCr 137.38Cr 134.48Cr 5.79TCr 213.55Cr 32Cr 29Cr 27Cr 24Cr 45Cr 3.05TCr 45Cr 317.66Cr 126.52Cr 1.6TCr 120.19Cr 117.66Cr 5.07TCr
Net income 23Cr 3.49Cr 3.13Cr 2.9Cr 2.62Cr 4.9Cr 332.5Cr 4.96Cr 35Cr 14Cr 173.99Cr 13Cr 13Cr 552.35Cr 38Cr 5.65Cr 5.07Cr 4.69Cr 4.25Cr 7.93Cr 538.41Cr 8.03Cr 56Cr 22Cr 281.74Cr 21Cr 21Cr 894.41Cr
Net Debt -51Cr -7.63Cr -6.85Cr -6.33Cr -5.73Cr -11Cr -726.65Cr -11Cr -76Cr -30Cr -380.24Cr -29Cr -28Cr -1.21TCr -84Cr -13Cr -11Cr -10Cr -9.44Cr -18Cr -1.2TCr -18Cr -124.66Cr -50Cr -626.45Cr -47Cr -46Cr -1.99TCr
Projected Income Statement - Annual - Harbin Gloria Pharmaceuticals Co., Ltd
Logo Harbin Gloria Pharmaceuticals Co., Ltd
HARBIN GLORIA PHARMACEUTICALS Co Ltd is a China-based company principally engaged in the research, development, production and sale of pharmaceuticals. The Company operates its businesses through three segments. The Traditional Chinese Medicine segment's main product is Annao Pills and Tablets. The Chemical Pharmaceuticals segment's products include cardiovascular and cerebrovascular drugs, musculoskeletal drugs, vitamins, electrolytes, analgesics, anti-infectives, anti-tumor drugs and others. The Others segment engages in pharmaceutical research and development, clinical services and others. The Company distributes its products within the domestic market and to overseas markets.
Employees
2,350
Date Price Change Volume
28/26/28 CN¥2.950 +1.37% 14,23,05,400
27/26/27 CN¥2.910 -3.32% 11,81,66,342
26/26/26 CN¥3.010 -2.27% 13,63,98,152
23/26/23 CN¥3.080 +1.32% 20,34,69,986
22/26/22 CN¥3.040 -6.17% 24,22,67,717

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Harbin Gloria Pharmaceuticals Co., Ltd
  1. Stock Market
  2. Stocks
  3. 002437 Stock